Skip to main content
. Author manuscript; available in PMC: 2018 Feb 6.
Published in final edited form as: J Neurosci Res. 2013 Aug 1;91(10):1292–1302. doi: 10.1002/jnr.23253

Fig. 3.

Fig. 3

BCG treatment does not change striatal levels of DA or 5-HT or their metabolites. Animals were sacrificed at 21 days following administration of either saline or 1 × 106 cfu BCG, i.p. (nine mice/group). Striatal levels of DA and 5-HT and their metabolites were analyzed by HPLC. There were no statistically significant differences between the two treatments for any measured parameter: DA, 3-O-methyldopamine (3-O-Me dopamine), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-HT, or 5-hydroxyindoleacetic acid (5-HIAA).